
Sign up to save your podcasts
Or
We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
Subscribe to the podcast!
Apple | Spotify | YouTube
4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
Subscribe to the podcast!
Apple | Spotify | YouTube
765 Listeners
807 Listeners
4,256 Listeners
32,030 Listeners
124 Listeners
271 Listeners
318 Listeners
697 Listeners
88 Listeners
31 Listeners
147 Listeners
11 Listeners
15 Listeners
149 Listeners
48 Listeners